ECM
ARIA

Estabrook Capital Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Estabrook Capital Management’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-110
Closed -$906 – 466
2015
Q1 		$906 Buy
+110
New +$813 ﹤0.01% 431

Other funds holding ARIA

SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Estabrook Capital Management's ARIA Position: Q2 2015 in Review

Estabrook Capital Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q2 2015, closing a stake of 110 shares — an estimated $906 sold.

Estabrook Capital Management first reported a position in ARIA in Q1 2015 and held it in 1 quarter. The position peaked at $906 in Q1 2015. 177 funds tracked by Wall St. Rank hold ARIA as of Q2 2015.

  • Estabrook Capital Management reported no remaining Ariad Pharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • Estabrook Capital Management sold 110 Ariad Pharmaceuticals Inc shares in Q2 2015, an estimated $906.
  • Estabrook Capital Management first reported a position in Ariad Pharmaceuticals Inc in Q1 2015 and held it in 1 quarter.
  • Estabrook Capital Management's Ariad Pharmaceuticals Inc position peaked at $906 in Q1 2015.
  • 177 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q2 2015.

Based on Estabrook Capital Management's 13F filing for Q2 2015, filed 11 Aug 2015.